Authors: Tobias F Jakobs RalfThorsten Hoffmann Angelika Schrader Hans Joachim Stemmler Christoph Trumm Andreas Lubienski Ravi Murthy Thomas K Helmberger Maximilian F Reiser
Publish Date: 2008/06/25
Volume: 32, Issue: 1, Pages: 38-46
Abstract
The purpose of this study was to evaluate technical success technique effectiveness and survival following radiofrequency ablation for breast cancer liver metastases and to determine prognostic factors Fortythree patients with 111 breast cancer liver metastases underwent CTguided percutaneous radiofrequency RF ablation Technical success and technique effectiveness was evaluated by performing serial CT scans We assessed the prognostic value of hormone receptor status overexpression of human epidermal growth factor receptor 2 HER2 and presence of extrahepatic tumor spread Survival rates were calculated using the Kaplan–Meier method Technical success was achieved in 107 metastases 96 Primary technique effectiveness was 96 During followup local tumor progression was observed in 15 metastases representing a secondary technique effectiveness of 865 The overall time to progression to the liver was 105 months The estimated overall median survival was 586 months There was no significant difference in terms of survival probability with respect to hormone receptor status HER2 overexpression and presence of isolated bone metastases Survival was significantly lower among patients with extrahepatic disease with the exception of skeletal metastases We conclude that CTguided RF ablation of liver metastases from breast cancer can be performed with a high degree of technical success and technique effectiveness providing promising survival rates in patients with no visceral extrahepatic disease Solitary bone metastases did not negatively affect survival probability after RF ablation
Keywords: